PF-Atlas › Clinical Trials › NCT06635850

A Study of Mosliciguat in PH-ILD

Mosliciguat · ANZCTR · Phase 2

Registry ID
NCT06635850
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
Mosliciguat
Mechanism
ANZCTR
Sponsor
Pulmovant, Inc.
Start
2024-10-29

About this trial

Mosliciguat is evaluated in NCT06635850, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Pulmovant, Inc., targeting anzctr. Current status: Active, not recruiting.

View NCT06635850 on ClinicalTrials.gov →

Explore related

All Mosliciguat trialsANZCTR mechanismAll IPF trials

Related trials

Ifenprodil — NCT04318704Inhaled mannitol — NCT00669331PTI-808 — NCT03251092BI 1819479 — NCT06335303AP01 — NCT06951217CMS — NCT03093974
Medical disclaimer. This page summarizes public trial data for NCT06635850 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.